MediPal Holdings stock closed at ¥2,791 today after a flat week in the market, even as fresh Q1 2027 numbers landed. The near term tape looks muted. The headline is that earnings power in this healthcare distributor remains steady rather than spectacular, with basic earnings per share at ¥66.66 and quarterly net income of ¥13.65b on revenue just under ¥1t.
For you as a longer term investor, the more important story sits in the trailing 12 month figures. Earnings per share of ¥227.21 and net income of ¥46.59b frame a business that still runs on thin margins, so every small shift in profitability matters for where MediPal Holdings trades next.
Is MediPal Holdings trading at a genuine discount, or is it carrying a low P/E label for valid reasons? See how its thin margins and DCF gap compare in our valuation analysis for MediPal Holdings
Q1 2027 Earnings Summary
- Revenue (Q1 2027 vs Q1 2026): ¥989,503m vs. ¥945,159m (steady year-on-year increase)
- Net Income (Excl. Extra Items, Q1 2027 vs Q1 2026): ¥13,646m vs. ¥9,586m (solid year-on-year uplift)
- Basic EPS (Q1 2027 vs Q1 2026): ¥66.66 vs. ¥46.17 (clear year-on-year improvement)
- Net Profit Margin (Trailing 12 Months vs Prior Year): 1.2% vs. 1.1% (slight margin expansion on thin profitability)
Prefer clean visuals over staring at thin margins and EPS figures in a spreadsheet? See MediPal Holdings' full financial picture, including a clear view of its profitability and valuation trade off, in our company report for MediPal Holdings.
MediPal earnings and the defensive upside story
MediPal Holdings still looks like a defensive healthcare backbone when you line the story up against the latest results. Revenue is close to ¥1t and net income of ¥13.65b, with EPS of ¥66.66 in the quarter and ¥227.21 over 12 months, points to a business that is consistently profitable, even on thin margins. Recent news around higher FY26 profit attributable to owners and lifted dividend guidance into FY27 backs the idea of steady earnings power and shareholder returns, helped by full consolidation of Paltac over time.
Where the MediPal bear case still bites
The bearish angle on MediPal Holdings focuses on thin margins and restructuring noise. The trailing net margin of 1.2% only edges above 1.1%, so this remains a volume driven model where small cost shocks matter. Management has already cut FY27 operating and ordinary profit forecasts due to Paltac related costs, which shows how easily profitability can be pressured. The Q1 numbers confirm that earnings are positive but do not yet resolve concerns about structurally low margins or the complexity of integrating a large wholesaler into an already diversified group.
Reveal where the surface looks calm, but the multi year models for MediPal Holdings start to disagree. Access the full revenue, earnings and cash flow analyst estimates for MediPal Holdings.Stay Ahead With Simply Wall St
If MediPal Holdings' thin margins and muted share price action have you watching for a better entry point, register for free with Simply Wall St and add it to your Watchlist to track price against fair value and key fundamentals. After you own the stock, use the Portfolio Command Center to cut through noise and focus on the updates that matter for your holdings. For a broader view on sentiment, tap into the Community to see how other investors are thinking about MediPal Holdings and similar stocks. This can help you spot potential catalysts or risks earlier and keep a step ahead of the market.
Seeking Alternatives Beyond MediPal Holdings
Fresh stock ideas can move from quiet to breakout before most investors react. Use these screeners while the data is still under the radar for now and consider them promptly.
- Identify resilient potential compounders early by scanning a curated 56 resilient stocks with low risk scores list before momentum stories become crowded and prices move away from your ideal entry range.
- Track the next wave in automation by following hand picked 36 robotics and automation stocks that may gain momentum as factories, warehouses and services upgrade.
- Review carefully filtered 37 power grid technology and infrastructure stocks candidates linked to the energy grid upgrade theme before it becomes mainstream and valuations adjust.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com